Rosuvastatin: A review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels

American Journal of Cardiovascular Drugs

Volumn 10, Issue 6, 2010, Pages 383-400

  Carter, Natalie J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; C reactive protein inhibitors; Cardiovascular disorders; prevention; Rosuvastatin; therapeutic use

Indexed keywords

ALUMINUM HYDROXIDE; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; C REACTIVE PROTEIN; CYCLOSPORIN; DIGOXIN; ETHINYLESTRADIOL; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FOSAMPRENAVIR PLUS RITONAVIR; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM HYDROXIDE; NICOTINIC ACID; NORGESTIMATE; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; RITONAVIR PLUS TIPRANAVIR; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; GROUPS BY AGE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; JAUNDICE; KIDNEY DYSFUNCTION; MYALGIA; MYOGLOBINURIA; MYOPATHY; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SEX RATIO; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRIMIDINES; SULFONAMIDES;

EID: 78649373209     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11204600-000000000-00000     Document Type: Review

References (82)

1. American Heart Association. Heart disease and stroke statistics: 2010 update at-a-glance [online]. Available from URL: http://www.americanheart.org/ downloadable/heart/1265665152970DS-3241%20HeartStrokeUpdate-2010. pdf [Accessed 2010 May 12]
2. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002 Jul 16; 106 (3): 388-91
3. U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. preventive services task force recommendation statement. Ann Intern Med 2009 Oct 6; 151 (7): 474-82
4. National Cholesterol Education Program. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): executive summary [online]. Available from URL: http://www.nhlbi.nih.gov/ guidelines/cholesterol/atp3xsum.pdf [Accessed 2010 May 12]
5. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003 Aug 20; 290 (7): 898-904
6. Ridker PM. Moving toward new statin guidelines in a post-JUPITER world: principles to consider. Curr Atheroscler Rep 2009 Jul; 11 (4): 249-56
7. Keating GM, Robinson DM. Rosuvastatin: a review of its effect on atherosclerosis. Am J Cardiovasc Drug 2008; 8 (2): 127-46
8. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999 Jul 20; 100 (3): 230-5
9. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001 Jul 4; 286 (1): 64-70
10. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998 Sep 1; 98 (9): 839-44
11. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005 Jan 6; 352 (1): 20-8
12. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation 2006 Jul 25; 114 (4): 281-8
13. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol #70mg/dl and C-reactive protein #2mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005 May 17; 45(10): 1644-8
14. Ridker PM, on behalf of the JUPITER study group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003 Nov 11; 108 (19): 2292-7
15. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 Nov 20; 359 (21): 2195-207
16. AstraZeneca. Crestor® (rosuvastatin calcium) tablets: highlights of the US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2010/021366s016lbl.pdf [Accessed 2010 May 12]
17. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002; 62 (14): 2075-85
18. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4 (2): 117-38
19. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010 Jan; 87 (1): 130-3
20. Tomlinson B, Hu M, Lee VWY, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther 2010; 87: 558-62
21. Hu M, Lui SSH, Mak VWL, et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet Genomics. Epub 2010 Jul 31
22. Bailey KM, Romaine SPR, Jackson BM, et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 study. Circ Cardiovasc Genet 2010; 3 (276-285)
23. Hall AS, Jackson BM, Farrin AJ, et al. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the secondary prevention of acute coronary events reduction of cholesterol to key European targets trial. Cardiovasc Prev Rehabil 2009 Dec; 16 (6): 712-21
24. Simonson SG, Martin PD, Mitchell PD, et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005 Aug; 45 (8): 927-34
25. Martin PD, Warwick MJ, Dane AL, et al. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003 Aug; 25 (8): 2215-24
26. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003 Oct; 25 (10): 2553-63
27. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration inhealthy volunteers.Br J Clin Pharmacol 2002 Nov; 54 (5): 472-7
28. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003Nov; 25 (11): 2822-35
29. Schuster H. Rosuvastatin-a highly effective new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40mg doses in dyslipidemic patients. Cardiology 2003; 99 (3): 126-39
30. McCormick AD, McKillop D, Butters CJ, et al. ZD452: an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract no. 46]. J Clin Pharmacol 2000 Sep; 40 (9): 1055
31. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002 Oct; 42 (10): 1116-21
32. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005 Oct; 78 (4): 330-41
33. Zhang W, Yu B-N, He Y-J, et al. Role of BCRP 421C#A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006 Nov; 373 (1-2): 99-103
34. Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009 Aug; 86 (2): 197-203
35. Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokineticsofrosuvastatin. Eur J Clin Pharmacol 2003 May;59(1): 51-6
36. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003 Jan; 55 (1): 94-9
37. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003 Apr; 73 (4): 322-9
38. Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002 Nov; 58 (8): 527-31
39. Martin PD, Dane AL, Schneck DW, et al. An open-label, randomized, threeway crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003 Feb; 25 (2): 459-71
40. Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004; 20 (8): 1185-95
41. Gosai P, Liu J, Doyle RT, et al. Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. Expert Opin Pharmacother 2008 Dec; 9 (17): 2947-53
42. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004 May; 75 (5): 455-63
43. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008 Apr 15; 47 (5): 570-8
44. Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin (in 605-610]. J Cardiovasc Pharmacol 2008 Jun; (51): 6
45. Pham PA, la Porte CJL, Lee LS, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009 Oct; 53 (10): 4385-92
46. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004 Aug; 76 (2): 167-77
47. Martin PD, Schneck DW, Dane AL, et al. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin 2008; 24 (4): 1231-5
48. Martin PD, Kemp J, Dane AL, et al. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002 Dec; 42 (12): 1352-7
49. Simonson SG, Martin PD, Warwick MJ, et al. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol 2003 Mar; 57 (3): 279-86
50. Ridker PM, Fonseca FAH, Genest J, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007 Dec 1; 100 (11): 1659-64
51. Ridker PM, MacFadyen JG, Fonseca FAH, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2009 Nov; 2 (6): 616-23
52. Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009 Apr 30; 360 (18): 1851-61
53. Everett BM, Glynn RJ, MacFadyen JG, et al. Rosuvastatininthe prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010 Jan 5; 121 (1): 143-50
54. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010 Apr 20; 152 (8): 488-96
55. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010 Mar 9; 121 (9): 1069-77
56. Pradhan A, Glynn RJ, Ridker PM. Prevention of major cardiovascular events with rosuvastatin among patients with impaired fasting glucose: the JUPITER trial [abstract no. 1425]. Circulation 2009 Nov 3; 120 (18 Suppl. 1): S500
57. Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein. J Am Coll Cardiol 2010 Mar 23; 55 (12): 1266-73
58. Ridker PM, MacFadyen J, Libby P, et al. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 2010 Jul 15; 106 (2): 204-9
59. Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010 Jul; 376 (9738): 333-9
60. Ridker PM, Danielson E, Fonseca FAH, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009 Apr 4; 373 (9670): 1175-82
61. Ridker PM, Rifai N, Clearfield M, et al. Measurement ofC-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001 Jun 28; 344 (26): 1959-65
62. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998 May 27; 279 (20): 1615-22
63. Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107 (4): 433-43
64. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 Aug 10; 355 (6): 549-59
65. Kahn R, Robertson RM, Smith R, et al. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008 Jul 29; 118 (5): 576-85
66. National Cholesterol Education Program. Your guide to lowering your cho-lesterol with TLC [online]. Available from URL: http://www.nhlbi.nih.gov/ health/public/heart/chol/chol-tlc.pdf [Accessed 2010 Sep 7]
67. Buckley DI, Fu R, Freeman M. C-Reactive proteinasarisk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009 Oct 6; 151 (7): 483-95
68. Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein choles-terol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of statins in primary Prevention: in Intervention Trial Evaluating Rosuvastatin) study. J Am Coll Cardiol 2009 Mar 17; 53 (11): 931-5
69. Plaisance EP, Grandjean PW. Physical activity and high-sensitivity C-reactive protein. Sports Med 2006; 36 (5): 443-58
70. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002 Mar 5; 105 (9): 1135-43
71. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003 Jan 28; 107 (3): 499-511
72. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J 2010 Apr; 31 (7): 777-83
73. Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem 2009 Feb; 55 (2): 305-12
74. Koenig W. Is hsCRP back on board? Implications from the JUPITER trial. Clin Chem 2009 Feb; 55 (2): 216-8
75. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syn-drome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003 Jan 28; 107 (3): 391-7
76. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scien-tific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7 Suppl. 1: 332-9
77. Danchin N. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial [letter]. Lancet 2009 Jul 4; 374 (9683): 24-5
78. Jackson G, Citrome L. JUPITER: wake up and smell the coffee-the absolute and relative merits of statin use. Int J Clin Pract 2009 Mar; 63 (3): 347-8
79. Mitka M. Studies examine inflammatory biomarker in prevention and pre-diction of heart disease. JAMA 2009 Jan 7; 301 (1): 23-4
80. Peters SAE, Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med. Epub 2010 Mar 6
81. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007 Mar 28; 297 (12): 1344-53
82. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010 Feb 27; 375 (9716): 735-42